

## Data supplement

**Table DS1** Efficacy variables: results of repeated measures and LOCF end-point analyses

Efficacy variables	Pregabalin		Placebo		<i>P</i> <sup>a</sup>
	<i>n</i>	LS mean change (s.e.)	<i>n</i>	LS mean change (s.e.)	
HRSA total score					
Baseline	177	26.7 (0.4)	96	26.2 (0.4)	
Week 2	153	−9.8 (0.6)	89	−7.2 (0.8)	0.0052
Week 4	148	−11.8 (0.6)	85	−9.1 (0.8)	0.0043
Week 6	139	−13.4 (0.6)	74	−10.3 (0.8)	0.0011
Week 8	120	−14.4 (0.6)	62	−11.6 (0.8)	0.0070
LOCF end-point	171	−12.8 (0.7)	95	−10.7 (0.9)	0.0437
HRSA psychic factor					
Baseline	171	14.4 (0.2)	95	14.3 (0.3)	
Week 2	153	−5.6 (0.3)	89	−3.9 (0.4)	0.0019
Week 4	148	−6.6 (0.4)	85	−4.9 (0.5)	0.0021
Week 6	139	−7.4 (0.4)	74	−5.6 (0.5)	0.0014
Week 8	120	−7.8 (0.4)	62	−6.3 (0.5)	0.0111
LOCF end-point	171	−7.0 (0.4)	95	−5.6 (0.5)	0.0242
HRSA somatic factor					
Baseline	171	12.2 (0.2)	95	11.8 (0.3)	
Week 2	153	−4.2 (0.3)	89	−3.3 (0.4)	0.0679
Week 4	148	−5.3 (0.3)	85	−4.2 (0.4)	0.0487
Week 6	139	−6.0 (0.3)	74	−4.7 (0.4)	0.0094
Week 8	120	−6.6 (0.3)	62	−5.4 (0.5)	0.0248
LOCF end-point	171	−5.9 (0.3)	95	−5.0 (0.4)	0.0956
CGI-I					
Week 2	154	2.7 (0.1)	90	3.1 (0.1)	0.0015
Week 4	149	2.6 (0.1)	86	3.0 (0.1)	0.0035
Week 6	139	2.3 (0.1)	74	2.7 (0.1)	0.0034
Week 8	121	2.3 (0.1)	62	2.7 (0.1)	0.0075
LOCF end-point	171	2.5 (0.1)	95	2.8 (0.1)	0.0382

CGI, Clinical Global Impression – Improvement scale; HRSA, Hamilton Rating Scale for Anxiety; LOCF, last observation carried forward; LS mean, least-squares mean.  
a. Nominal *P*-values are shown for secondary efficacy measures, unadjusted for multiplicity.